ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

Rhea-AI Summary

ALX Oncology (NASDAQ: ALXO), a clinical-stage biotech company focused on developing cancer therapies, has announced its participation in the upcoming Jefferies 2025 Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, June 5, 2025, at 1:25 PM ET in New York. Investors and interested parties can access the live webcast through ALX Oncology's website investor section, with a replay available for up to 90 days after the event. The conference presentation provides an opportunity for ALX Oncology to showcase its pipeline of novel cancer therapies aimed at treating cancer and extending patient survival.

News Market Reaction

+3.92%

1 alert

+3.92% News Effect

On the day this news was published, ALXO gained 3.92%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows:

Format: Fireside Chat
Date: Thursday, June 5, 2025
Time: 1:25 PM ET
Location: New York, NY
Webcast link: Available here

The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577

FAQ

When is ALX Oncology (ALXO) presenting at the Jefferies Healthcare Conference 2025?

ALX Oncology will present at the Jefferies Healthcare Conference on Thursday, June 5, 2025, at 1:25 PM ET in New York.

How can I watch ALX Oncology's (ALXO) Jefferies conference presentation?

The presentation can be accessed through the live webcast available in the Investors section of ALX Oncology's website at www.alxoncology.com under Events and Presentations.

How long will ALX Oncology's (ALXO) Jefferies conference presentation be available for replay?

A replay of the webcast will be archived and available for up to 90 days following the fireside chat.

What type of company is ALX Oncology (ALXO)?

ALX Oncology is a clinical-stage biotechnology company that develops novel therapies designed to treat cancer and extend patients' lives.